AbbVie Signs a Research Agreement with Idera Pharmaceuticals to Evaluate Combination Therapy

Shots:

• AbbVie and Idera collaborated to conduct clinical study evaluating the combination of ABBV-368 + tilsotolimod + CT or ABBV-181. AbbVie will be responsible for conducting the trial while Idera to provide clinical trial supply of tilsotolimod
• The P-Ib study will evaluate the safety, tolerability, PK and preliminary efficacy of ABBV-368 plus tilsotolimod in three different arms in patients with recurrent or metastatic head and neck squamous cell carcinoma
• Abbvie’s ABBV-368 is anti-OX40 mab, being evaluated in P-I study for solid tumors. ABBV-181 is an anti-PD1 mAb, being developed in combinations with other AbbVie’s molecules for solid tumors and hematologic malignancies while tilsotolimod is a TLR-9 agonist developed by Idera for multiple cancer indications

Click here to­ read full press release/ article | Ref: Idera | Image: Chicago Tribune